Breast Cancer
The links below provide further information on each researcher and their work.
- Nottingham Breast Institute
- Cancer Autoimmunity (CEAC)
|
Cancer epigenetics; cancer stem cells; cancer reprogramming
|
|
Breast tumour biomarkers; Nottingham Prognostic Index |
| Prof John Robertson |
Immune biomarkers; early detection; lung and breast tumours |
| Dr Anna Grabowska |
Pre-clinical cancer modelling/imaging; target validation; tumour microenvironment |
|
Breast cancer; molecular pathology; tissue microarrays; immunohistochemistry; prognosis |
|
Prognostic and predictive biomarkers; lymphatic biology and metastasis; radiation biology/radiotherapy; calpains and calpastatin
|
|
|
DNA repair; base excision repair; APE1 inhibitors; stratified medicine;
cancer biomarkers |
|
Annexins; anti-tumour agents; POT1 kinase; telomerase inhibitors
|
| |
Androgen receptor; Estrogen receptor; REX1/ZFP42; cancer stem cells; prostate cancer |
| Dr Steve Chan |
Clinical oncology |
| Dr Caroline Chapman |
Immune biomarkers; B-cells; stem cells; tumour associated antigens |
|
Breast cancer: molecular pathology, classification and outcome |
|
Dr Nicole Clarke
|
Tumour suppressor IRF1 function; IRF target genes |
| |
Histone acetyltransferases; chromatin modification; Nuclear Receptors; BCL11A; PRAME |
| Dr Rajendra Kumari |
Pre-clinical cancer modelling; bioimaging; tumour microenvironment; targeted therapies |